Rifampicin: not always an innocent drug.
Dafni SveroniAggelos StefosEirini I RigopoulouGeorgios N DalekosPublished in: BMJ case reports (2018)
Rifampicin has been widely used due to its broad antibacterial spectrum. Acute haemolysis is a rarely encountered complication of rifampicin. A 58-year-old woman was admitted to our department because of high-grade fever with rigors, accompanied by abdominal and lumbar pain and laboratory evidence of acute haemolysis. She had been treated for brucellosis initially with doxycycline and streptomycin. Due to subsequent appearance of myositis, ciprofloxacin and rifampicin were added for treatment of localised brucellosis. After intravenous administration of rifampicin, the patient deteriorated significantly. After exclusion of other causes of haemolysis, autoimmune haemolytic anaemia related to rifampicin was established by strongly positive direct Coombs test. Drug withdrawal in conjunction with intravenous immune globulin and prednisolone resulted in resolution of haemolysis and no relapse in the ensuing 1-year period. Our case highlights the importance of recognising commonly administrative drugs as cause of haemolytic anaemia, that can often be life threatening.
Keyphrases
- mycobacterium tuberculosis
- pulmonary tuberculosis
- drug induced
- high grade
- liver failure
- high dose
- respiratory failure
- multiple sclerosis
- emergency department
- case report
- aortic dissection
- rheumatoid arthritis
- spinal cord
- hepatitis b virus
- adverse drug
- pain management
- systemic sclerosis
- mechanical ventilation
- electronic health record
- interstitial lung disease